摘要
目的探讨亮菌口服溶液联合酪酸梭菌活菌散治疗新生儿病理性黄疸的临床疗效。方法选取2022年12月至2024年12月在郑州市妇幼保健院住院的新生儿病理性黄疸患儿80例,采用随机数字表法分为对照组和观察组,每组40例。对照组口服酪酸梭菌活菌散,观察组在对照组治疗基础上加服亮菌口服溶液。两组均连续治疗7 d后判定疗效。比较两组黄疸消退时间、血清总胆红素水平、CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、不良反应及再入院情况。结果观察组治疗有效率高于对照组,黄疸消退时间短于对照组,差异有统计学意义(P<0.05)。治疗3 d、7 d后,观察组血清总胆红素水平均低于同期对照组,差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,差异有统计学意义(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。出院1个月后随访,两组均未发生不良反应,且无再入院病例。结论亮菌口服溶液联合酪酸梭菌活菌散治疗新生儿病理性黄疸有较好疗效,可促进黄疸消退,降低血清总胆红素水平,改善患儿免疫功能,且安全性良好。
Objective To investigate the clinical efficacy of Liangjun oral solution combined with Clostridium butyricum live bacterial powder in the treatment of neonatal pathological jaundice.Methods A total of 80 hospitalized neonates with pathological jaundice admitted to Zhengzhou Maternal and Child Health Care Hospital from December 2022 to December 2024 were enrolled and randomly allocated by a random number table into a control group and an observation group.with 40 cases in each group.The control group received oral Clostridium butyricum live bacterial powder.while the observation group received Liangjun oral solution in addition to the treatment given to the control group.Both groups were treated continuously for 7 days.after which therapeutic efficacy was evaluated.Jaundice resolution time.serum total bilirubin(TBil)levels.CD3^(+).CD4^(+).CD8^(+).CD4^(+)/CD8^(+)ratio.adverse reactions.and readmission were compared between the two groups.Results The overall response rate in the observation group was higher than that in the control group.and the jaundice resolution time was shorter in the observation group than in the control group;the differences were statistically significant(P<0.05).After 3 and 7 days of treatment.serum TBil levels in the observation group were lower than those in the control group at the corresponding time points.with statistically significant differences(P<0.05).After treatment.the observation group had higher levels of CD3^(+).CD4^(+).and CD4^(+)/CD8^(+)than the control group.whereas CD8^(+)was lower than that in the control group;the differences were statistically significant(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).At the 1-month postdischarge follow-up.no adverse reactions occurred in either group.and no readmissions were reported.Conclusion Liangjun oral solution combined with Clostridium butyricum live bacterial powder shows good efficacy in the treatment of neonatal pathological jaundice.This regimen can promote jaundice resolution.reduce serum total bilirubin levels.improve immune function in affected neonates.and has a favorable safety profile.
作者
刘方方
王倩
张晓敏
谭鑫
LIU Fangfang;WANG Qian;ZHANG Xiaomin;TAN Xin(Department of Neonatology,Zhengzhou Maternal and Child Health Care Hospital,Zhengzhou Henan 450000,China)
出处
《临床研究》
2026年第2期65-68,共4页
Clinical Research
关键词
亮菌口服溶液
酪酸梭菌活菌散
新生儿病理性黄疸
临床效果
Liangjun oral solution
Clostridium butyricum live bacterial powder
neonatal pathological jaundice
clinical efficacy
